Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $100000.0.

  • Aclaris Therapeutics' Gains from Investment Securities fell 9844.85% to $100000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.2 million, marking a year-over-year decrease of 52201.74%. This contributed to the annual value of $6.7 million for FY2024, which is 471.24% up from last year.
  • Latest data reveals that Aclaris Therapeutics reported Gains from Investment Securities of $100000.0 as of Q3 2025, which was down 9844.85% from $11.3 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Gains from Investment Securities ranged from a high of $16.4 million in Q1 2021 and a low of -$26.3 million during Q4 2023
  • Over the past 5 years, Aclaris Therapeutics' median Gains from Investment Securities value was $4.9 million (recorded in 2022), while the average stood at $3.2 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 47042.25% in 2023, then skyrocketed by 97087.25% in 2024.
  • Over the past 5 years, Aclaris Therapeutics' Gains from Investment Securities (Quarter) stood at $2.2 million in 2021, then surged by 222.73% to $7.1 million in 2022, then crashed by 470.42% to -$26.3 million in 2023, then soared by 95.06% to -$1.3 million in 2024, then surged by 107.69% to $100000.0 in 2025.
  • Its last three reported values are $100000.0 in Q3 2025, $11.3 million for Q2 2025, and $300000.0 during Q1 2025.